Global Viral Vector-Based Gene Therapy Drugs Market 2024 by Company, Regions, Type and Application, Forecast to 2030
Viral vector-based gene therapy drugs are pharmaceutical products that use viral vectors to deliver therapeutic genes into target cells for the treatment of genetic disorders or diseases. These drugs typically contain modified viruses as vectors to efficiently and safely transfer genetic material into the cells of patients, aiming to correct genetic mutations or induce specific therapeutic effects.
According to our (Global Info Research) latest study, the global Viral Vector-Based Gene Therapy Drugs market size was valued at US$ million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of %during review period.
This report is a detailed and comprehensive analysis for global Viral Vector-Based Gene Therapy Drugs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global Viral Vector-Based Gene Therapy Drugs market size and forecasts, in consumption value ($ Million), 2019-2030
Global Viral Vector-Based Gene Therapy Drugs market size and forecasts by region and country, in consumption value ($ Million), 2019-2030
Global Viral Vector-Based Gene Therapy Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030
Global Viral Vector-Based Gene Therapy Drugs market shares of main players, in revenue ($ Million), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Viral Vector-Based Gene Therapy Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Viral Vector-Based Gene Therapy Drugs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GSK, MolMed, GILD, JW Therapeutics, Sibiono, Latima, Novartis, Bluebird Bio, Thermo Fisher Scientific, Intas, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Viral Vector-Based Gene Therapy Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segmentation
Viral Vector-Based Gene Therapy Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Viral Vector-Based Gene Therapy Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Viral Vector-Based Gene Therapy Drugs, with revenue, gross margin, and global market share of Viral Vector-Based Gene Therapy Drugs from 2019 to 2024.
Chapter 3, the Viral Vector-Based Gene Therapy Drugs competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Viral Vector-Based Gene Therapy Drugs market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Viral Vector-Based Gene Therapy Drugs.
Chapter 13, to describe Viral Vector-Based Gene Therapy Drugs research findings and conclusion.
According to our (Global Info Research) latest study, the global Viral Vector-Based Gene Therapy Drugs market size was valued at US$ million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of %during review period.
This report is a detailed and comprehensive analysis for global Viral Vector-Based Gene Therapy Drugs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global Viral Vector-Based Gene Therapy Drugs market size and forecasts, in consumption value ($ Million), 2019-2030
Global Viral Vector-Based Gene Therapy Drugs market size and forecasts by region and country, in consumption value ($ Million), 2019-2030
Global Viral Vector-Based Gene Therapy Drugs market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030
Global Viral Vector-Based Gene Therapy Drugs market shares of main players, in revenue ($ Million), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Viral Vector-Based Gene Therapy Drugs
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Viral Vector-Based Gene Therapy Drugs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GSK, MolMed, GILD, JW Therapeutics, Sibiono, Latima, Novartis, Bluebird Bio, Thermo Fisher Scientific, Intas, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Viral Vector-Based Gene Therapy Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segmentation
Viral Vector-Based Gene Therapy Drugs market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
- Retroviral Vector
- Adenovirus Vector
- Lentiviral Vector
- Others
- Hospital
- Diagnostic and Testing Laboratories
- Academic and Research Organizations
- Others
- GSK
- MolMed
- GILD
- JW Therapeutics
- Sibiono
- Latima
- Novartis
- Bluebird Bio
- Thermo Fisher Scientific
- Intas
- BMS
- Orchard Therapeutics
- Shanghai Sunway Biotech
- uniQure
- Spark Therapeutics
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Viral Vector-Based Gene Therapy Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Viral Vector-Based Gene Therapy Drugs, with revenue, gross margin, and global market share of Viral Vector-Based Gene Therapy Drugs from 2019 to 2024.
Chapter 3, the Viral Vector-Based Gene Therapy Drugs competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Viral Vector-Based Gene Therapy Drugs market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Viral Vector-Based Gene Therapy Drugs.
Chapter 13, to describe Viral Vector-Based Gene Therapy Drugs research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Viral Vector-Based Gene Therapy Drugs by Type
1.3.1 Overview: Global Viral Vector-Based Gene Therapy Drugs Market Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Type in 2023
1.3.3 Retroviral Vector
1.3.4 Adenovirus Vector
1.3.5 Lentiviral Vector
1.3.6 Others
1.4 Global Viral Vector-Based Gene Therapy Drugs Market by Application
1.4.1 Overview: Global Viral Vector-Based Gene Therapy Drugs Market Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospital
1.4.3 Diagnostic and Testing Laboratories
1.4.4 Academic and Research Organizations
1.4.5 Others
1.5 Global Viral Vector-Based Gene Therapy Drugs Market Size & Forecast
1.6 Global Viral Vector-Based Gene Therapy Drugs Market Size and Forecast by Region
1.6.1 Global Viral Vector-Based Gene Therapy Drugs Market Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Viral Vector-Based Gene Therapy Drugs Market Size by Region, (2019-2030)
1.6.3 North America Viral Vector-Based Gene Therapy Drugs Market Size and Prospect (2019-2030)
1.6.4 Europe Viral Vector-Based Gene Therapy Drugs Market Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Viral Vector-Based Gene Therapy Drugs Market Size and Prospect (2019-2030)
1.6.6 South America Viral Vector-Based Gene Therapy Drugs Market Size and Prospect (2019-2030)
1.6.7 Middle East & Africa Viral Vector-Based Gene Therapy Drugs Market Size and Prospect (2019-2030)
2 COMPANY PROFILES
2.1 GSK
2.1.1 GSK Details
2.1.2 GSK Major Business
2.1.3 GSK Viral Vector-Based Gene Therapy Drugs Product and Solutions
2.1.4 GSK Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 GSK Recent Developments and Future Plans
2.2 MolMed
2.2.1 MolMed Details
2.2.2 MolMed Major Business
2.2.3 MolMed Viral Vector-Based Gene Therapy Drugs Product and Solutions
2.2.4 MolMed Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 MolMed Recent Developments and Future Plans
2.3 GILD
2.3.1 GILD Details
2.3.2 GILD Major Business
2.3.3 GILD Viral Vector-Based Gene Therapy Drugs Product and Solutions
2.3.4 GILD Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 GILD Recent Developments and Future Plans
2.4 JW Therapeutics
2.4.1 JW Therapeutics Details
2.4.2 JW Therapeutics Major Business
2.4.3 JW Therapeutics Viral Vector-Based Gene Therapy Drugs Product and Solutions
2.4.4 JW Therapeutics Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 JW Therapeutics Recent Developments and Future Plans
2.5 Sibiono
2.5.1 Sibiono Details
2.5.2 Sibiono Major Business
2.5.3 Sibiono Viral Vector-Based Gene Therapy Drugs Product and Solutions
2.5.4 Sibiono Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Sibiono Recent Developments and Future Plans
2.6 Latima
2.6.1 Latima Details
2.6.2 Latima Major Business
2.6.3 Latima Viral Vector-Based Gene Therapy Drugs Product and Solutions
2.6.4 Latima Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Latima Recent Developments and Future Plans
2.7 Novartis
2.7.1 Novartis Details
2.7.2 Novartis Major Business
2.7.3 Novartis Viral Vector-Based Gene Therapy Drugs Product and Solutions
2.7.4 Novartis Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Novartis Recent Developments and Future Plans
2.8 Bluebird Bio
2.8.1 Bluebird Bio Details
2.8.2 Bluebird Bio Major Business
2.8.3 Bluebird Bio Viral Vector-Based Gene Therapy Drugs Product and Solutions
2.8.4 Bluebird Bio Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Bluebird Bio Recent Developments and Future Plans
2.9 Thermo Fisher Scientific
2.9.1 Thermo Fisher Scientific Details
2.9.2 Thermo Fisher Scientific Major Business
2.9.3 Thermo Fisher Scientific Viral Vector-Based Gene Therapy Drugs Product and Solutions
2.9.4 Thermo Fisher Scientific Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Thermo Fisher Scientific Recent Developments and Future Plans
2.10 Intas
2.10.1 Intas Details
2.10.2 Intas Major Business
2.10.3 Intas Viral Vector-Based Gene Therapy Drugs Product and Solutions
2.10.4 Intas Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Intas Recent Developments and Future Plans
2.11 BMS
2.11.1 BMS Details
2.11.2 BMS Major Business
2.11.3 BMS Viral Vector-Based Gene Therapy Drugs Product and Solutions
2.11.4 BMS Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.11.5 BMS Recent Developments and Future Plans
2.12 Orchard Therapeutics
2.12.1 Orchard Therapeutics Details
2.12.2 Orchard Therapeutics Major Business
2.12.3 Orchard Therapeutics Viral Vector-Based Gene Therapy Drugs Product and Solutions
2.12.4 Orchard Therapeutics Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.12.5 Orchard Therapeutics Recent Developments and Future Plans
2.13 Shanghai Sunway Biotech
2.13.1 Shanghai Sunway Biotech Details
2.13.2 Shanghai Sunway Biotech Major Business
2.13.3 Shanghai Sunway Biotech Viral Vector-Based Gene Therapy Drugs Product and Solutions
2.13.4 Shanghai Sunway Biotech Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.13.5 Shanghai Sunway Biotech Recent Developments and Future Plans
2.14 uniQure
2.14.1 uniQure Details
2.14.2 uniQure Major Business
2.14.3 uniQure Viral Vector-Based Gene Therapy Drugs Product and Solutions
2.14.4 uniQure Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.14.5 uniQure Recent Developments and Future Plans
2.15 Spark Therapeutics
2.15.1 Spark Therapeutics Details
2.15.2 Spark Therapeutics Major Business
2.15.3 Spark Therapeutics Viral Vector-Based Gene Therapy Drugs Product and Solutions
2.15.4 Spark Therapeutics Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.15.5 Spark Therapeutics Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Viral Vector-Based Gene Therapy Drugs Revenue and Share by Players (2019-2024)
3.2 Market Share Analysis (2023)
3.2.1 Market Share of Viral Vector-Based Gene Therapy Drugs by Company Revenue
3.2.2 Top 3 Viral Vector-Based Gene Therapy Drugs Players Market Share in 2023
3.2.3 Top 6 Viral Vector-Based Gene Therapy Drugs Players Market Share in 2023
3.3 Viral Vector-Based Gene Therapy Drugs Market: Overall Company Footprint Analysis
3.3.1 Viral Vector-Based Gene Therapy Drugs Market: Region Footprint
3.3.2 Viral Vector-Based Gene Therapy Drugs Market: Company Product Type Footprint
3.3.3 Viral Vector-Based Gene Therapy Drugs Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Viral Vector-Based Gene Therapy Drugs Consumption Value and Market Share by Type (2019-2024)
4.2 Global Viral Vector-Based Gene Therapy Drugs Market Forecast by Type (2025-2030)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Application (2019-2024)
5.2 Global Viral Vector-Based Gene Therapy Drugs Market Forecast by Application (2025-2030)
6 NORTH AMERICA
6.1 North America Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2019-2030)
6.2 North America Viral Vector-Based Gene Therapy Drugs Market Size by Application (2019-2030)
6.3 North America Viral Vector-Based Gene Therapy Drugs Market Size by Country
6.3.1 North America Viral Vector-Based Gene Therapy Drugs Consumption Value by Country (2019-2030)
6.3.2 United States Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
6.3.3 Canada Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
6.3.4 Mexico Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
7 EUROPE
7.1 Europe Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2019-2030)
7.2 Europe Viral Vector-Based Gene Therapy Drugs Consumption Value by Application (2019-2030)
7.3 Europe Viral Vector-Based Gene Therapy Drugs Market Size by Country
7.3.1 Europe Viral Vector-Based Gene Therapy Drugs Consumption Value by Country (2019-2030)
7.3.2 Germany Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
7.3.3 France Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
7.3.4 United Kingdom Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
7.3.5 Russia Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
7.3.6 Italy Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
8 ASIA-PACIFIC
8.1 Asia-Pacific Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Viral Vector-Based Gene Therapy Drugs Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Viral Vector-Based Gene Therapy Drugs Market Size by Region
8.3.1 Asia-Pacific Viral Vector-Based Gene Therapy Drugs Consumption Value by Region (2019-2030)
8.3.2 China Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
8.3.3 Japan Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
8.3.4 South Korea Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
8.3.5 India Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
8.3.6 Southeast Asia Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
8.3.7 Australia Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
9 SOUTH AMERICA
9.1 South America Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2019-2030)
9.2 South America Viral Vector-Based Gene Therapy Drugs Consumption Value by Application (2019-2030)
9.3 South America Viral Vector-Based Gene Therapy Drugs Market Size by Country
9.3.1 South America Viral Vector-Based Gene Therapy Drugs Consumption Value by Country (2019-2030)
9.3.2 Brazil Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
9.3.3 Argentina Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Viral Vector-Based Gene Therapy Drugs Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Viral Vector-Based Gene Therapy Drugs Market Size by Country
10.3.1 Middle East & Africa Viral Vector-Based Gene Therapy Drugs Consumption Value by Country (2019-2030)
10.3.2 Turkey Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
10.3.4 UAE Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
11 MARKET DYNAMICS
11.1 Viral Vector-Based Gene Therapy Drugs Market Drivers
11.2 Viral Vector-Based Gene Therapy Drugs Market Restraints
11.3 Viral Vector-Based Gene Therapy Drugs Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Viral Vector-Based Gene Therapy Drugs Industry Chain
12.2 Viral Vector-Based Gene Therapy Drugs Upstream Analysis
12.3 Viral Vector-Based Gene Therapy Drugs Midstream Analysis
12.4 Viral Vector-Based Gene Therapy Drugs Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Viral Vector-Based Gene Therapy Drugs by Type
1.3.1 Overview: Global Viral Vector-Based Gene Therapy Drugs Market Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Type in 2023
1.3.3 Retroviral Vector
1.3.4 Adenovirus Vector
1.3.5 Lentiviral Vector
1.3.6 Others
1.4 Global Viral Vector-Based Gene Therapy Drugs Market by Application
1.4.1 Overview: Global Viral Vector-Based Gene Therapy Drugs Market Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Hospital
1.4.3 Diagnostic and Testing Laboratories
1.4.4 Academic and Research Organizations
1.4.5 Others
1.5 Global Viral Vector-Based Gene Therapy Drugs Market Size & Forecast
1.6 Global Viral Vector-Based Gene Therapy Drugs Market Size and Forecast by Region
1.6.1 Global Viral Vector-Based Gene Therapy Drugs Market Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Viral Vector-Based Gene Therapy Drugs Market Size by Region, (2019-2030)
1.6.3 North America Viral Vector-Based Gene Therapy Drugs Market Size and Prospect (2019-2030)
1.6.4 Europe Viral Vector-Based Gene Therapy Drugs Market Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Viral Vector-Based Gene Therapy Drugs Market Size and Prospect (2019-2030)
1.6.6 South America Viral Vector-Based Gene Therapy Drugs Market Size and Prospect (2019-2030)
1.6.7 Middle East & Africa Viral Vector-Based Gene Therapy Drugs Market Size and Prospect (2019-2030)
2 COMPANY PROFILES
2.1 GSK
2.1.1 GSK Details
2.1.2 GSK Major Business
2.1.3 GSK Viral Vector-Based Gene Therapy Drugs Product and Solutions
2.1.4 GSK Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 GSK Recent Developments and Future Plans
2.2 MolMed
2.2.1 MolMed Details
2.2.2 MolMed Major Business
2.2.3 MolMed Viral Vector-Based Gene Therapy Drugs Product and Solutions
2.2.4 MolMed Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 MolMed Recent Developments and Future Plans
2.3 GILD
2.3.1 GILD Details
2.3.2 GILD Major Business
2.3.3 GILD Viral Vector-Based Gene Therapy Drugs Product and Solutions
2.3.4 GILD Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 GILD Recent Developments and Future Plans
2.4 JW Therapeutics
2.4.1 JW Therapeutics Details
2.4.2 JW Therapeutics Major Business
2.4.3 JW Therapeutics Viral Vector-Based Gene Therapy Drugs Product and Solutions
2.4.4 JW Therapeutics Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 JW Therapeutics Recent Developments and Future Plans
2.5 Sibiono
2.5.1 Sibiono Details
2.5.2 Sibiono Major Business
2.5.3 Sibiono Viral Vector-Based Gene Therapy Drugs Product and Solutions
2.5.4 Sibiono Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 Sibiono Recent Developments and Future Plans
2.6 Latima
2.6.1 Latima Details
2.6.2 Latima Major Business
2.6.3 Latima Viral Vector-Based Gene Therapy Drugs Product and Solutions
2.6.4 Latima Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 Latima Recent Developments and Future Plans
2.7 Novartis
2.7.1 Novartis Details
2.7.2 Novartis Major Business
2.7.3 Novartis Viral Vector-Based Gene Therapy Drugs Product and Solutions
2.7.4 Novartis Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Novartis Recent Developments and Future Plans
2.8 Bluebird Bio
2.8.1 Bluebird Bio Details
2.8.2 Bluebird Bio Major Business
2.8.3 Bluebird Bio Viral Vector-Based Gene Therapy Drugs Product and Solutions
2.8.4 Bluebird Bio Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Bluebird Bio Recent Developments and Future Plans
2.9 Thermo Fisher Scientific
2.9.1 Thermo Fisher Scientific Details
2.9.2 Thermo Fisher Scientific Major Business
2.9.3 Thermo Fisher Scientific Viral Vector-Based Gene Therapy Drugs Product and Solutions
2.9.4 Thermo Fisher Scientific Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 Thermo Fisher Scientific Recent Developments and Future Plans
2.10 Intas
2.10.1 Intas Details
2.10.2 Intas Major Business
2.10.3 Intas Viral Vector-Based Gene Therapy Drugs Product and Solutions
2.10.4 Intas Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Intas Recent Developments and Future Plans
2.11 BMS
2.11.1 BMS Details
2.11.2 BMS Major Business
2.11.3 BMS Viral Vector-Based Gene Therapy Drugs Product and Solutions
2.11.4 BMS Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.11.5 BMS Recent Developments and Future Plans
2.12 Orchard Therapeutics
2.12.1 Orchard Therapeutics Details
2.12.2 Orchard Therapeutics Major Business
2.12.3 Orchard Therapeutics Viral Vector-Based Gene Therapy Drugs Product and Solutions
2.12.4 Orchard Therapeutics Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.12.5 Orchard Therapeutics Recent Developments and Future Plans
2.13 Shanghai Sunway Biotech
2.13.1 Shanghai Sunway Biotech Details
2.13.2 Shanghai Sunway Biotech Major Business
2.13.3 Shanghai Sunway Biotech Viral Vector-Based Gene Therapy Drugs Product and Solutions
2.13.4 Shanghai Sunway Biotech Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.13.5 Shanghai Sunway Biotech Recent Developments and Future Plans
2.14 uniQure
2.14.1 uniQure Details
2.14.2 uniQure Major Business
2.14.3 uniQure Viral Vector-Based Gene Therapy Drugs Product and Solutions
2.14.4 uniQure Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.14.5 uniQure Recent Developments and Future Plans
2.15 Spark Therapeutics
2.15.1 Spark Therapeutics Details
2.15.2 Spark Therapeutics Major Business
2.15.3 Spark Therapeutics Viral Vector-Based Gene Therapy Drugs Product and Solutions
2.15.4 Spark Therapeutics Viral Vector-Based Gene Therapy Drugs Revenue, Gross Margin and Market Share (2019-2024)
2.15.5 Spark Therapeutics Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Viral Vector-Based Gene Therapy Drugs Revenue and Share by Players (2019-2024)
3.2 Market Share Analysis (2023)
3.2.1 Market Share of Viral Vector-Based Gene Therapy Drugs by Company Revenue
3.2.2 Top 3 Viral Vector-Based Gene Therapy Drugs Players Market Share in 2023
3.2.3 Top 6 Viral Vector-Based Gene Therapy Drugs Players Market Share in 2023
3.3 Viral Vector-Based Gene Therapy Drugs Market: Overall Company Footprint Analysis
3.3.1 Viral Vector-Based Gene Therapy Drugs Market: Region Footprint
3.3.2 Viral Vector-Based Gene Therapy Drugs Market: Company Product Type Footprint
3.3.3 Viral Vector-Based Gene Therapy Drugs Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Viral Vector-Based Gene Therapy Drugs Consumption Value and Market Share by Type (2019-2024)
4.2 Global Viral Vector-Based Gene Therapy Drugs Market Forecast by Type (2025-2030)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Application (2019-2024)
5.2 Global Viral Vector-Based Gene Therapy Drugs Market Forecast by Application (2025-2030)
6 NORTH AMERICA
6.1 North America Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2019-2030)
6.2 North America Viral Vector-Based Gene Therapy Drugs Market Size by Application (2019-2030)
6.3 North America Viral Vector-Based Gene Therapy Drugs Market Size by Country
6.3.1 North America Viral Vector-Based Gene Therapy Drugs Consumption Value by Country (2019-2030)
6.3.2 United States Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
6.3.3 Canada Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
6.3.4 Mexico Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
7 EUROPE
7.1 Europe Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2019-2030)
7.2 Europe Viral Vector-Based Gene Therapy Drugs Consumption Value by Application (2019-2030)
7.3 Europe Viral Vector-Based Gene Therapy Drugs Market Size by Country
7.3.1 Europe Viral Vector-Based Gene Therapy Drugs Consumption Value by Country (2019-2030)
7.3.2 Germany Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
7.3.3 France Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
7.3.4 United Kingdom Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
7.3.5 Russia Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
7.3.6 Italy Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
8 ASIA-PACIFIC
8.1 Asia-Pacific Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Viral Vector-Based Gene Therapy Drugs Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Viral Vector-Based Gene Therapy Drugs Market Size by Region
8.3.1 Asia-Pacific Viral Vector-Based Gene Therapy Drugs Consumption Value by Region (2019-2030)
8.3.2 China Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
8.3.3 Japan Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
8.3.4 South Korea Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
8.3.5 India Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
8.3.6 Southeast Asia Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
8.3.7 Australia Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
9 SOUTH AMERICA
9.1 South America Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2019-2030)
9.2 South America Viral Vector-Based Gene Therapy Drugs Consumption Value by Application (2019-2030)
9.3 South America Viral Vector-Based Gene Therapy Drugs Market Size by Country
9.3.1 South America Viral Vector-Based Gene Therapy Drugs Consumption Value by Country (2019-2030)
9.3.2 Brazil Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
9.3.3 Argentina Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Viral Vector-Based Gene Therapy Drugs Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Viral Vector-Based Gene Therapy Drugs Market Size by Country
10.3.1 Middle East & Africa Viral Vector-Based Gene Therapy Drugs Consumption Value by Country (2019-2030)
10.3.2 Turkey Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
10.3.4 UAE Viral Vector-Based Gene Therapy Drugs Market Size and Forecast (2019-2030)
11 MARKET DYNAMICS
11.1 Viral Vector-Based Gene Therapy Drugs Market Drivers
11.2 Viral Vector-Based Gene Therapy Drugs Market Restraints
11.3 Viral Vector-Based Gene Therapy Drugs Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Viral Vector-Based Gene Therapy Drugs Industry Chain
12.2 Viral Vector-Based Gene Therapy Drugs Upstream Analysis
12.3 Viral Vector-Based Gene Therapy Drugs Midstream Analysis
12.4 Viral Vector-Based Gene Therapy Drugs Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Viral Vector-Based Gene Therapy Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Viral Vector-Based Gene Therapy Drugs Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Global Viral Vector-Based Gene Therapy Drugs Consumption Value by Region (2019-2024) & (USD Million)
Table 4. Global Viral Vector-Based Gene Therapy Drugs Consumption Value by Region (2025-2030) & (USD Million)
Table 5. GSK Company Information, Head Office, and Major Competitors
Table 6. GSK Major Business
Table 7. GSK Viral Vector-Based Gene Therapy Drugs Product and Solutions
Table 8. GSK Viral Vector-Based Gene Therapy Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 9. GSK Recent Developments and Future Plans
Table 10. MolMed Company Information, Head Office, and Major Competitors
Table 11. MolMed Major Business
Table 12. MolMed Viral Vector-Based Gene Therapy Drugs Product and Solutions
Table 13. MolMed Viral Vector-Based Gene Therapy Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 14. MolMed Recent Developments and Future Plans
Table 15. GILD Company Information, Head Office, and Major Competitors
Table 16. GILD Major Business
Table 17. GILD Viral Vector-Based Gene Therapy Drugs Product and Solutions
Table 18. GILD Viral Vector-Based Gene Therapy Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 19. JW Therapeutics Company Information, Head Office, and Major Competitors
Table 20. JW Therapeutics Major Business
Table 21. JW Therapeutics Viral Vector-Based Gene Therapy Drugs Product and Solutions
Table 22. JW Therapeutics Viral Vector-Based Gene Therapy Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 23. JW Therapeutics Recent Developments and Future Plans
Table 24. Sibiono Company Information, Head Office, and Major Competitors
Table 25. Sibiono Major Business
Table 26. Sibiono Viral Vector-Based Gene Therapy Drugs Product and Solutions
Table 27. Sibiono Viral Vector-Based Gene Therapy Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 28. Sibiono Recent Developments and Future Plans
Table 29. Latima Company Information, Head Office, and Major Competitors
Table 30. Latima Major Business
Table 31. Latima Viral Vector-Based Gene Therapy Drugs Product and Solutions
Table 32. Latima Viral Vector-Based Gene Therapy Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 33. Latima Recent Developments and Future Plans
Table 34. Novartis Company Information, Head Office, and Major Competitors
Table 35. Novartis Major Business
Table 36. Novartis Viral Vector-Based Gene Therapy Drugs Product and Solutions
Table 37. Novartis Viral Vector-Based Gene Therapy Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 38. Novartis Recent Developments and Future Plans
Table 39. Bluebird Bio Company Information, Head Office, and Major Competitors
Table 40. Bluebird Bio Major Business
Table 41. Bluebird Bio Viral Vector-Based Gene Therapy Drugs Product and Solutions
Table 42. Bluebird Bio Viral Vector-Based Gene Therapy Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 43. Bluebird Bio Recent Developments and Future Plans
Table 44. Thermo Fisher Scientific Company Information, Head Office, and Major Competitors
Table 45. Thermo Fisher Scientific Major Business
Table 46. Thermo Fisher Scientific Viral Vector-Based Gene Therapy Drugs Product and Solutions
Table 47. Thermo Fisher Scientific Viral Vector-Based Gene Therapy Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 48. Thermo Fisher Scientific Recent Developments and Future Plans
Table 49. Intas Company Information, Head Office, and Major Competitors
Table 50. Intas Major Business
Table 51. Intas Viral Vector-Based Gene Therapy Drugs Product and Solutions
Table 52. Intas Viral Vector-Based Gene Therapy Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 53. Intas Recent Developments and Future Plans
Table 54. BMS Company Information, Head Office, and Major Competitors
Table 55. BMS Major Business
Table 56. BMS Viral Vector-Based Gene Therapy Drugs Product and Solutions
Table 57. BMS Viral Vector-Based Gene Therapy Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 58. BMS Recent Developments and Future Plans
Table 59. Orchard Therapeutics Company Information, Head Office, and Major Competitors
Table 60. Orchard Therapeutics Major Business
Table 61. Orchard Therapeutics Viral Vector-Based Gene Therapy Drugs Product and Solutions
Table 62. Orchard Therapeutics Viral Vector-Based Gene Therapy Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 63. Orchard Therapeutics Recent Developments and Future Plans
Table 64. Shanghai Sunway Biotech Company Information, Head Office, and Major Competitors
Table 65. Shanghai Sunway Biotech Major Business
Table 66. Shanghai Sunway Biotech Viral Vector-Based Gene Therapy Drugs Product and Solutions
Table 67. Shanghai Sunway Biotech Viral Vector-Based Gene Therapy Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 68. Shanghai Sunway Biotech Recent Developments and Future Plans
Table 69. uniQure Company Information, Head Office, and Major Competitors
Table 70. uniQure Major Business
Table 71. uniQure Viral Vector-Based Gene Therapy Drugs Product and Solutions
Table 72. uniQure Viral Vector-Based Gene Therapy Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 73. uniQure Recent Developments and Future Plans
Table 74. Spark Therapeutics Company Information, Head Office, and Major Competitors
Table 75. Spark Therapeutics Major Business
Table 76. Spark Therapeutics Viral Vector-Based Gene Therapy Drugs Product and Solutions
Table 77. Spark Therapeutics Viral Vector-Based Gene Therapy Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 78. Spark Therapeutics Recent Developments and Future Plans
Table 79. Global Viral Vector-Based Gene Therapy Drugs Revenue (USD Million) by Players (2019-2024)
Table 80. Global Viral Vector-Based Gene Therapy Drugs Revenue Share by Players (2019-2024)
Table 81. Breakdown of Viral Vector-Based Gene Therapy Drugs by Company Type (Tier 1, Tier 2, and Tier 3)
Table 82. Market Position of Players in Viral Vector-Based Gene Therapy Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
Table 83. Head Office of Key Viral Vector-Based Gene Therapy Drugs Players
Table 84. Viral Vector-Based Gene Therapy Drugs Market: Company Product Type Footprint
Table 85. Viral Vector-Based Gene Therapy Drugs Market: Company Product Application Footprint
Table 86. Viral Vector-Based Gene Therapy Drugs New Market Entrants and Barriers to Market Entry
Table 87. Viral Vector-Based Gene Therapy Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 88. Global Viral Vector-Based Gene Therapy Drugs Consumption Value (USD Million) by Type (2019-2024)
Table 89. Global Viral Vector-Based Gene Therapy Drugs Consumption Value Share by Type (2019-2024)
Table 90. Global Viral Vector-Based Gene Therapy Drugs Consumption Value Forecast by Type (2025-2030)
Table 91. Global Viral Vector-Based Gene Therapy Drugs Consumption Value by Application (2019-2024)
Table 92. Global Viral Vector-Based Gene Therapy Drugs Consumption Value Forecast by Application (2025-2030)
Table 93. North America Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2019-2024) & (USD Million)
Table 94. North America Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2025-2030) & (USD Million)
Table 95. North America Viral Vector-Based Gene Therapy Drugs Consumption Value by Application (2019-2024) & (USD Million)
Table 96. North America Viral Vector-Based Gene Therapy Drugs Consumption Value by Application (2025-2030) & (USD Million)
Table 97. North America Viral Vector-Based Gene Therapy Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 98. North America Viral Vector-Based Gene Therapy Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 99. Europe Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2019-2024) & (USD Million)
Table 100. Europe Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2025-2030) & (USD Million)
Table 101. Europe Viral Vector-Based Gene Therapy Drugs Consumption Value by Application (2019-2024) & (USD Million)
Table 102. Europe Viral Vector-Based Gene Therapy Drugs Consumption Value by Application (2025-2030) & (USD Million)
Table 103. Europe Viral Vector-Based Gene Therapy Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 104. Europe Viral Vector-Based Gene Therapy Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 105. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2019-2024) & (USD Million)
Table 106. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2025-2030) & (USD Million)
Table 107. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Consumption Value by Application (2019-2024) & (USD Million)
Table 108. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Consumption Value by Application (2025-2030) & (USD Million)
Table 109. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Consumption Value by Region (2019-2024) & (USD Million)
Table 110. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Consumption Value by Region (2025-2030) & (USD Million)
Table 111. South America Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2019-2024) & (USD Million)
Table 112. South America Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2025-2030) & (USD Million)
Table 113. South America Viral Vector-Based Gene Therapy Drugs Consumption Value by Application (2019-2024) & (USD Million)
Table 114. South America Viral Vector-Based Gene Therapy Drugs Consumption Value by Application (2025-2030) & (USD Million)
Table 115. South America Viral Vector-Based Gene Therapy Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 116. South America Viral Vector-Based Gene Therapy Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 117. Middle East & Africa Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2019-2024) & (USD Million)
Table 118. Middle East & Africa Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2025-2030) & (USD Million)
Table 119. Middle East & Africa Viral Vector-Based Gene Therapy Drugs Consumption Value by Application (2019-2024) & (USD Million)
Table 120. Middle East & Africa Viral Vector-Based Gene Therapy Drugs Consumption Value by Application (2025-2030) & (USD Million)
Table 121. Middle East & Africa Viral Vector-Based Gene Therapy Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 122. Middle East & Africa Viral Vector-Based Gene Therapy Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 123. Global Key Players of Viral Vector-Based Gene Therapy Drugs Upstream (Raw Materials)
Table 124. Global Viral Vector-Based Gene Therapy Drugs Typical Customers
Table 1. Global Viral Vector-Based Gene Therapy Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Viral Vector-Based Gene Therapy Drugs Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Global Viral Vector-Based Gene Therapy Drugs Consumption Value by Region (2019-2024) & (USD Million)
Table 4. Global Viral Vector-Based Gene Therapy Drugs Consumption Value by Region (2025-2030) & (USD Million)
Table 5. GSK Company Information, Head Office, and Major Competitors
Table 6. GSK Major Business
Table 7. GSK Viral Vector-Based Gene Therapy Drugs Product and Solutions
Table 8. GSK Viral Vector-Based Gene Therapy Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 9. GSK Recent Developments and Future Plans
Table 10. MolMed Company Information, Head Office, and Major Competitors
Table 11. MolMed Major Business
Table 12. MolMed Viral Vector-Based Gene Therapy Drugs Product and Solutions
Table 13. MolMed Viral Vector-Based Gene Therapy Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 14. MolMed Recent Developments and Future Plans
Table 15. GILD Company Information, Head Office, and Major Competitors
Table 16. GILD Major Business
Table 17. GILD Viral Vector-Based Gene Therapy Drugs Product and Solutions
Table 18. GILD Viral Vector-Based Gene Therapy Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 19. JW Therapeutics Company Information, Head Office, and Major Competitors
Table 20. JW Therapeutics Major Business
Table 21. JW Therapeutics Viral Vector-Based Gene Therapy Drugs Product and Solutions
Table 22. JW Therapeutics Viral Vector-Based Gene Therapy Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 23. JW Therapeutics Recent Developments and Future Plans
Table 24. Sibiono Company Information, Head Office, and Major Competitors
Table 25. Sibiono Major Business
Table 26. Sibiono Viral Vector-Based Gene Therapy Drugs Product and Solutions
Table 27. Sibiono Viral Vector-Based Gene Therapy Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 28. Sibiono Recent Developments and Future Plans
Table 29. Latima Company Information, Head Office, and Major Competitors
Table 30. Latima Major Business
Table 31. Latima Viral Vector-Based Gene Therapy Drugs Product and Solutions
Table 32. Latima Viral Vector-Based Gene Therapy Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 33. Latima Recent Developments and Future Plans
Table 34. Novartis Company Information, Head Office, and Major Competitors
Table 35. Novartis Major Business
Table 36. Novartis Viral Vector-Based Gene Therapy Drugs Product and Solutions
Table 37. Novartis Viral Vector-Based Gene Therapy Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 38. Novartis Recent Developments and Future Plans
Table 39. Bluebird Bio Company Information, Head Office, and Major Competitors
Table 40. Bluebird Bio Major Business
Table 41. Bluebird Bio Viral Vector-Based Gene Therapy Drugs Product and Solutions
Table 42. Bluebird Bio Viral Vector-Based Gene Therapy Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 43. Bluebird Bio Recent Developments and Future Plans
Table 44. Thermo Fisher Scientific Company Information, Head Office, and Major Competitors
Table 45. Thermo Fisher Scientific Major Business
Table 46. Thermo Fisher Scientific Viral Vector-Based Gene Therapy Drugs Product and Solutions
Table 47. Thermo Fisher Scientific Viral Vector-Based Gene Therapy Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 48. Thermo Fisher Scientific Recent Developments and Future Plans
Table 49. Intas Company Information, Head Office, and Major Competitors
Table 50. Intas Major Business
Table 51. Intas Viral Vector-Based Gene Therapy Drugs Product and Solutions
Table 52. Intas Viral Vector-Based Gene Therapy Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 53. Intas Recent Developments and Future Plans
Table 54. BMS Company Information, Head Office, and Major Competitors
Table 55. BMS Major Business
Table 56. BMS Viral Vector-Based Gene Therapy Drugs Product and Solutions
Table 57. BMS Viral Vector-Based Gene Therapy Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 58. BMS Recent Developments and Future Plans
Table 59. Orchard Therapeutics Company Information, Head Office, and Major Competitors
Table 60. Orchard Therapeutics Major Business
Table 61. Orchard Therapeutics Viral Vector-Based Gene Therapy Drugs Product and Solutions
Table 62. Orchard Therapeutics Viral Vector-Based Gene Therapy Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 63. Orchard Therapeutics Recent Developments and Future Plans
Table 64. Shanghai Sunway Biotech Company Information, Head Office, and Major Competitors
Table 65. Shanghai Sunway Biotech Major Business
Table 66. Shanghai Sunway Biotech Viral Vector-Based Gene Therapy Drugs Product and Solutions
Table 67. Shanghai Sunway Biotech Viral Vector-Based Gene Therapy Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 68. Shanghai Sunway Biotech Recent Developments and Future Plans
Table 69. uniQure Company Information, Head Office, and Major Competitors
Table 70. uniQure Major Business
Table 71. uniQure Viral Vector-Based Gene Therapy Drugs Product and Solutions
Table 72. uniQure Viral Vector-Based Gene Therapy Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 73. uniQure Recent Developments and Future Plans
Table 74. Spark Therapeutics Company Information, Head Office, and Major Competitors
Table 75. Spark Therapeutics Major Business
Table 76. Spark Therapeutics Viral Vector-Based Gene Therapy Drugs Product and Solutions
Table 77. Spark Therapeutics Viral Vector-Based Gene Therapy Drugs Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 78. Spark Therapeutics Recent Developments and Future Plans
Table 79. Global Viral Vector-Based Gene Therapy Drugs Revenue (USD Million) by Players (2019-2024)
Table 80. Global Viral Vector-Based Gene Therapy Drugs Revenue Share by Players (2019-2024)
Table 81. Breakdown of Viral Vector-Based Gene Therapy Drugs by Company Type (Tier 1, Tier 2, and Tier 3)
Table 82. Market Position of Players in Viral Vector-Based Gene Therapy Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
Table 83. Head Office of Key Viral Vector-Based Gene Therapy Drugs Players
Table 84. Viral Vector-Based Gene Therapy Drugs Market: Company Product Type Footprint
Table 85. Viral Vector-Based Gene Therapy Drugs Market: Company Product Application Footprint
Table 86. Viral Vector-Based Gene Therapy Drugs New Market Entrants and Barriers to Market Entry
Table 87. Viral Vector-Based Gene Therapy Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 88. Global Viral Vector-Based Gene Therapy Drugs Consumption Value (USD Million) by Type (2019-2024)
Table 89. Global Viral Vector-Based Gene Therapy Drugs Consumption Value Share by Type (2019-2024)
Table 90. Global Viral Vector-Based Gene Therapy Drugs Consumption Value Forecast by Type (2025-2030)
Table 91. Global Viral Vector-Based Gene Therapy Drugs Consumption Value by Application (2019-2024)
Table 92. Global Viral Vector-Based Gene Therapy Drugs Consumption Value Forecast by Application (2025-2030)
Table 93. North America Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2019-2024) & (USD Million)
Table 94. North America Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2025-2030) & (USD Million)
Table 95. North America Viral Vector-Based Gene Therapy Drugs Consumption Value by Application (2019-2024) & (USD Million)
Table 96. North America Viral Vector-Based Gene Therapy Drugs Consumption Value by Application (2025-2030) & (USD Million)
Table 97. North America Viral Vector-Based Gene Therapy Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 98. North America Viral Vector-Based Gene Therapy Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 99. Europe Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2019-2024) & (USD Million)
Table 100. Europe Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2025-2030) & (USD Million)
Table 101. Europe Viral Vector-Based Gene Therapy Drugs Consumption Value by Application (2019-2024) & (USD Million)
Table 102. Europe Viral Vector-Based Gene Therapy Drugs Consumption Value by Application (2025-2030) & (USD Million)
Table 103. Europe Viral Vector-Based Gene Therapy Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 104. Europe Viral Vector-Based Gene Therapy Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 105. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2019-2024) & (USD Million)
Table 106. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2025-2030) & (USD Million)
Table 107. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Consumption Value by Application (2019-2024) & (USD Million)
Table 108. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Consumption Value by Application (2025-2030) & (USD Million)
Table 109. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Consumption Value by Region (2019-2024) & (USD Million)
Table 110. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Consumption Value by Region (2025-2030) & (USD Million)
Table 111. South America Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2019-2024) & (USD Million)
Table 112. South America Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2025-2030) & (USD Million)
Table 113. South America Viral Vector-Based Gene Therapy Drugs Consumption Value by Application (2019-2024) & (USD Million)
Table 114. South America Viral Vector-Based Gene Therapy Drugs Consumption Value by Application (2025-2030) & (USD Million)
Table 115. South America Viral Vector-Based Gene Therapy Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 116. South America Viral Vector-Based Gene Therapy Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 117. Middle East & Africa Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2019-2024) & (USD Million)
Table 118. Middle East & Africa Viral Vector-Based Gene Therapy Drugs Consumption Value by Type (2025-2030) & (USD Million)
Table 119. Middle East & Africa Viral Vector-Based Gene Therapy Drugs Consumption Value by Application (2019-2024) & (USD Million)
Table 120. Middle East & Africa Viral Vector-Based Gene Therapy Drugs Consumption Value by Application (2025-2030) & (USD Million)
Table 121. Middle East & Africa Viral Vector-Based Gene Therapy Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 122. Middle East & Africa Viral Vector-Based Gene Therapy Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 123. Global Key Players of Viral Vector-Based Gene Therapy Drugs Upstream (Raw Materials)
Table 124. Global Viral Vector-Based Gene Therapy Drugs Typical Customers
LIST OF FIGURES
Figure 1. Viral Vector-Based Gene Therapy Drugs Picture
Figure 2. Global Viral Vector-Based Gene Therapy Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Type in 2023
Figure 4. Retroviral Vector
Figure 5. Adenovirus Vector
Figure 6. Lentiviral Vector
Figure 7. Others
Figure 8. Global Viral Vector-Based Gene Therapy Drugs Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 9. Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Application in 2023
Figure 10. Hospital Picture
Figure 11. Diagnostic and Testing Laboratories Picture
Figure 12. Academic and Research Organizations Picture
Figure 13. Others Picture
Figure 14. Global Viral Vector-Based Gene Therapy Drugs Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 15. Global Viral Vector-Based Gene Therapy Drugs Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 16. Global Market Viral Vector-Based Gene Therapy Drugs Consumption Value (USD Million) Comparison by Region (2019 VS 2023 VS 2030)
Figure 17. Global Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Region (2019-2030)
Figure 18. Global Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Region in 2023
Figure 19. North America Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 20. Europe Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 21. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 22. South America Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 23. Middle East & Africa Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 24. Company Three Recent Developments and Future Plans
Figure 25. Global Viral Vector-Based Gene Therapy Drugs Revenue Share by Players in 2023
Figure 26. Viral Vector-Based Gene Therapy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2023
Figure 27. Market Share of Viral Vector-Based Gene Therapy Drugs by Player Revenue in 2023
Figure 28. Top 3 Viral Vector-Based Gene Therapy Drugs Players Market Share in 2023
Figure 29. Top 6 Viral Vector-Based Gene Therapy Drugs Players Market Share in 2023
Figure 30. Global Viral Vector-Based Gene Therapy Drugs Consumption Value Share by Type (2019-2024)
Figure 31. Global Viral Vector-Based Gene Therapy Drugs Market Share Forecast by Type (2025-2030)
Figure 32. Global Viral Vector-Based Gene Therapy Drugs Consumption Value Share by Application (2019-2024)
Figure 33. Global Viral Vector-Based Gene Therapy Drugs Market Share Forecast by Application (2025-2030)
Figure 34. North America Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Type (2019-2030)
Figure 35. North America Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Application (2019-2030)
Figure 36. North America Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Country (2019-2030)
Figure 37. United States Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 38. Canada Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 39. Mexico Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 40. Europe Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Type (2019-2030)
Figure 41. Europe Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Application (2019-2030)
Figure 42. Europe Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Country (2019-2030)
Figure 43. Germany Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 44. France Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 45. United Kingdom Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 46. Russia Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 47. Italy Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 48. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Type (2019-2030)
Figure 49. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Application (2019-2030)
Figure 50. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Region (2019-2030)
Figure 51. China Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 52. Japan Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 53. South Korea Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 54. India Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 55. Southeast Asia Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 56. Australia Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 57. South America Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Type (2019-2030)
Figure 58. South America Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Application (2019-2030)
Figure 59. South America Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Country (2019-2030)
Figure 60. Brazil Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 61. Argentina Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 62. Middle East & Africa Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Type (2019-2030)
Figure 63. Middle East & Africa Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Application (2019-2030)
Figure 64. Middle East & Africa Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Country (2019-2030)
Figure 65. Turkey Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 66. Saudi Arabia Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 67. UAE Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 68. Viral Vector-Based Gene Therapy Drugs Market Drivers
Figure 69. Viral Vector-Based Gene Therapy Drugs Market Restraints
Figure 70. Viral Vector-Based Gene Therapy Drugs Market Trends
Figure 71. Porters Five Forces Analysis
Figure 72. Viral Vector-Based Gene Therapy Drugs Industrial Chain
Figure 73. Methodology
Figure 74. Research Process and Data Source
Figure 1. Viral Vector-Based Gene Therapy Drugs Picture
Figure 2. Global Viral Vector-Based Gene Therapy Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Type in 2023
Figure 4. Retroviral Vector
Figure 5. Adenovirus Vector
Figure 6. Lentiviral Vector
Figure 7. Others
Figure 8. Global Viral Vector-Based Gene Therapy Drugs Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 9. Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Application in 2023
Figure 10. Hospital Picture
Figure 11. Diagnostic and Testing Laboratories Picture
Figure 12. Academic and Research Organizations Picture
Figure 13. Others Picture
Figure 14. Global Viral Vector-Based Gene Therapy Drugs Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 15. Global Viral Vector-Based Gene Therapy Drugs Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 16. Global Market Viral Vector-Based Gene Therapy Drugs Consumption Value (USD Million) Comparison by Region (2019 VS 2023 VS 2030)
Figure 17. Global Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Region (2019-2030)
Figure 18. Global Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Region in 2023
Figure 19. North America Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 20. Europe Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 21. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 22. South America Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 23. Middle East & Africa Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 24. Company Three Recent Developments and Future Plans
Figure 25. Global Viral Vector-Based Gene Therapy Drugs Revenue Share by Players in 2023
Figure 26. Viral Vector-Based Gene Therapy Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2023
Figure 27. Market Share of Viral Vector-Based Gene Therapy Drugs by Player Revenue in 2023
Figure 28. Top 3 Viral Vector-Based Gene Therapy Drugs Players Market Share in 2023
Figure 29. Top 6 Viral Vector-Based Gene Therapy Drugs Players Market Share in 2023
Figure 30. Global Viral Vector-Based Gene Therapy Drugs Consumption Value Share by Type (2019-2024)
Figure 31. Global Viral Vector-Based Gene Therapy Drugs Market Share Forecast by Type (2025-2030)
Figure 32. Global Viral Vector-Based Gene Therapy Drugs Consumption Value Share by Application (2019-2024)
Figure 33. Global Viral Vector-Based Gene Therapy Drugs Market Share Forecast by Application (2025-2030)
Figure 34. North America Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Type (2019-2030)
Figure 35. North America Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Application (2019-2030)
Figure 36. North America Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Country (2019-2030)
Figure 37. United States Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 38. Canada Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 39. Mexico Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 40. Europe Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Type (2019-2030)
Figure 41. Europe Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Application (2019-2030)
Figure 42. Europe Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Country (2019-2030)
Figure 43. Germany Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 44. France Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 45. United Kingdom Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 46. Russia Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 47. Italy Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 48. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Type (2019-2030)
Figure 49. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Application (2019-2030)
Figure 50. Asia-Pacific Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Region (2019-2030)
Figure 51. China Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 52. Japan Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 53. South Korea Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 54. India Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 55. Southeast Asia Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 56. Australia Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 57. South America Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Type (2019-2030)
Figure 58. South America Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Application (2019-2030)
Figure 59. South America Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Country (2019-2030)
Figure 60. Brazil Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 61. Argentina Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 62. Middle East & Africa Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Type (2019-2030)
Figure 63. Middle East & Africa Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Application (2019-2030)
Figure 64. Middle East & Africa Viral Vector-Based Gene Therapy Drugs Consumption Value Market Share by Country (2019-2030)
Figure 65. Turkey Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 66. Saudi Arabia Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 67. UAE Viral Vector-Based Gene Therapy Drugs Consumption Value (2019-2030) & (USD Million)
Figure 68. Viral Vector-Based Gene Therapy Drugs Market Drivers
Figure 69. Viral Vector-Based Gene Therapy Drugs Market Restraints
Figure 70. Viral Vector-Based Gene Therapy Drugs Market Trends
Figure 71. Porters Five Forces Analysis
Figure 72. Viral Vector-Based Gene Therapy Drugs Industrial Chain
Figure 73. Methodology
Figure 74. Research Process and Data Source
